Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly has morphed from a reliable pharma giant into a biotech powerhouse riding blockbuster success. Mounjaro and ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand access soon.

Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...

Patients have reported dental issues like tooth decay and dry mouth after taking GLP-1s like Ozempic for weight loss, though ...

In the marketing effort promoting Lilly’s Mounjaro, Stonestreet and his mother, Jamey, discuss living with type 2 diabetes and taking the GLP-1 for treatment.

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.